ATHA
Athira·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Ample Liquidity
RSI Oversold
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ATHA
Athira Pharma, Inc.
A biopharmaceutical company developing small molecule therapies for neurodegenerative diseases, with a focus on Alzheimer's disease
18706 North Creek Parkway, Suite 104, Bothell, Washington 98011
--
Athira Pharma, Inc., was incorporated as M3 Biotechnology, Inc., in Washington State on March 31, 2011, and re-registered as a joint stock company in Delaware on October 27, 2015. The company is an late-stage clinical biopharmaceutical company that develops small drug molecules to restore neuronal health and stop neurodegeneration. With the company's product candidates, it aims to provide rapid cognitive improvement and change the course of neurological diseases through its novel mechanism of action.
Company Financials
EPS
ATHA has released its 2025 Q3 earnings. EPS was reported at -1.68, versus the expected -1.22, missing expectations. The chart below visualizes how ATHA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
